CBP’s management prepared the Performance Summary Report and the related disclosures in accordance with the requirements of the Office of National Drug Control Policy’s (ONDCP) Circular, Accounting of Drug Control Funding and Performance Summary, dated January 18, 2013. Based on its review, nothing came to KPMG’s attention that caused it to believe that CBP’s FY 2016 Performance Summary Report is not presented in conformity with the criteria in ONDCP’s Circular. KPMG did not make any recommendations as a result of its review.
Consistent with CDC guidance, most Office of Inspector General employees are currently serving the American people remotely. We are determined to keep interruptions to our operations to a minimum, and we appreciate your patience during this time.
Information and guidance about COVID-19 is available at coronavirus.gov.